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Previously we demonstrated that addition of Tumour Necrosis Factor-a to melphalan or doxorubicin in a so-called isolated
limb perfusion results in synergistic antitumour responses of sarcomas in both animal models and patients. Yet, 20 to 30% of
the treated tumours do not respond. Therefore agents that synergise with tumour necrosis factor alpha must be investigated.
Actinomycin D is used in combination with melphalan in isolated limb perfusion in the treatment of patients with melanoma
in-transit metastases and is well known to augment tumour cell sensitivity towards tumour necrosis factor alpha in vitro. Both
agents are very toxic, which limits their systemic use. Their applicability may therefore be tested in the isolated limb perfusion
setting, by which the tumours can be exposed to high concentrations in the absence of systemic exposure. To study the
beneﬁcial effect of the combination in vivo, BN-175 soft tissue sarcoma-bearing rats were perfused with various concentrations
of actinomycin D and tumour necrosis factor alpha. When used alone the drugs had only little effect on the tumour. Only
when actinomycin D and tumour necrosis factor alpha were combined a tumour response was achieved. However, these
responses were accompanied by severe, dose limiting, local toxicity such as destruction of the muscle tissue and massive
oedema. Our results show that isolated limb perfusion with actinomycin D in combination with tumour necrosis factor alpha
leads to a synergistic anti-tumour response but also to idiosyncratic locoregional toxicity to the normal tissues. Actinomycin D,
in combination with tumour necrosis factor alpha, should not be explored in the clinical setting because of this. The standard
approach in the clinic remains isolated limb perfusion with tumour necrosis factor alpha in combination with melphalan.
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In 1958 Creech et al (1958) described the application of an isolated
limb perfusion (ILP) for the treatment of a patient with a melano-
ma in-transit metastases who refused amputation. Perfusions with
melphalan in these patients results in fairly good response rates in
contrast to patients with locally advanced extremity soft tissue
sarcomas (STS) (Eggermont, 1996a). The addition of tumour
necrosis factor-alpha (TNF) has dramatically changed the efﬁcacy
of the procedure in patients with extremity STS. Eggermont et al
(1996b,c) reported that in patients with advanced STS an ILP with
TNF + melphalan with Interferon-gamma or without interferon-
gamma improved tumour response rates to above 80% resulting
in a limb salvage in over 70% of the patients destined otherwise
to undergo an amputation. The results of the multicenter studies
in Europe eventually lead to the approval of TNF for this indica-
tion in Europe (Eggermont et al, 1999). Despite these good
results, still 20 to 30% of these patients do not respond to this
therapy and other agents that can further improve this treatment
must be identiﬁed.
In rat osteo- and soft tissue sarcoma ILP models we were able to
mimic the clinical ILP with comparable response type and rate
(Manusama et al, 1996). In this setting new drug combinations
can be tested rapidly. To improve response rates doxorubicin has
been used instead of melphalan. However, ILP with doxorubicin
in combination with TNF appeared less effective than melphalan
with TNF. Response rates were respectively 54 and 70% (de Wilt
et al, 1999; Van Der Veen et al, 2000).
Actinomycin D is an anticancer antibiotic that has been used in
combination with melphalan in the ILP setting in the treatment of
patients with melanoma in-transit metastases conﬁned to the extre-
mities. It is an interesting drug to evaluate in combination with
TNF because incubation of tumour cells with actinomycin D has
been shown to increase their sensitivity to the effects of TNF (Alex-
ander et al, 1987). Administration of TNF and actinomycin D in
mice delayed the growth of several tumours signiﬁcantly, but appli-
cation was limited due to the severe toxic effects (Mosende et al,
1977). Patients with osteogenic sarcoma have been treated with
actinomycin D in combination with bleomycin and cyclophospha-
mide. This treatment was associated with severe nausea and
anorexia (Lasek et al, 1996). With an ILP a high drug concentra-
tion can be administered with minimal systemic toxicity due to
negligible leakage to the rest of the body (Lienard et al, 1992).
In this way, melphalan has been used for many years as a single
drug treatment with a local concentration 15–20 times higher than
can be achieved by systemic treatment (Benckhuijsen et al, 1988).
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www.bjcancer.comIn the presented study we performed ILP with the combination
of actinomycin D and TNF to study their potential of inducing a
tumour response. In vitro studies were undertaken to examine
the direct effect of the agents on tumour cells.
MATERIALS AND METHODS
Animals
Male inbred BN rats, weighing 250–300 g, obtained from Harlan-
CPB (Austerlitz, the Netherlands) were used for isolated limb
perfusions. Rats were fed a standard laboratory diet ad libitum
(Hope Farms Woerden, the Netherlands) and were housed under
standard conditions. The experimental protocols adhered to the
rules outlined in the ‘Dutch Animal Experimentation Act’ (1977)
and the published ‘Guidelines of the UKCCCR for the welfare of
animals in experimental Neoplasia’ (UKCCCR, 1998). The protocol
was approved by the committee on Animal Research of the Eras-
mus University Rotterdam, the Netherlands.
Tumour model
The rapidly growing and metastasising BN-175 soft tissue sarcoma,
which is transplantable to the BN rat, was used. Fragments of 2–
3 mm were implanted subcutaneously in the right hind limb, just
above the ankle. Perfusion was performed at a tumour diameter of
13+2 mm, approximately 7 days after implantation. Tumour
growth was recorded by calliper measurements and the volume
was calculated with the formula 0.4 (A
26B), where B stands for
the largest diameter of the tumour and A the diameter perpendicu-
lar to B.
Drugs
Recombinant human TNF (rHuTNF) was provided by Boehringer
(Boehringer Ingelheim GmbH, Austria) with a speciﬁc activity of
5.8610
7 Um g
71 as determined in the murine L-M cell assay.
Endotoxin levels were 51.25 units (EU) per mg protein. TNF
concentrations used were 50 mg in 5 ml perfusate.
Actinomycin D (Sigma, the Netherlands) was diluted in phos-
phate buffered saline to a concentration of 2 mg ml
71.
Concentrations used were 5 and 10 mg in 5 ml perfusate.
Melphalan (Alkeran, Wellcome, Beckenham, UK) was diluted in
phosphate buffered saline to a concentration of 2 mg ml
71.
Concentrations used were 40 mg in 5 ml perfusate.
In vitro assessment of anti-tumour activity
Cells isolated from a BN-175 soft tissue sarcoma were maintained
in cell culture for a maximum of 20 passages in RPMI supplemen-
ted with 10% foetal bovine serum and L-glutamine. Media and
supplements were obtained from Life Technologies, the Nether-
lands.
BN soft tissue sarcoma cells were added in 100 ml aliquots to 96-
well plates at a ﬁnal concentration of 10
4 cells per well and allowed
to grow as a monolayer. Actinomycin D and rHuTNF, diluted in
RPMI supplement with 10% foetal bovine serum and L-glutamine,
were added to the wells and allowed to incubate for 3 days. The
range of ﬁnal drug concentration in the well was 0.05–
100 ng ml
71 for actinomycin D and 0–10000 ng ml
71 for
rHuTNF. As a control the TNF sensitive cell line WEHI-164 was
used. The cells were incubated in the presence of a concentration
of 0.05–100 ng ml
71 actinomycin D and 0–1 ng ml
71 TNF,
diluted in RPMI supplement with 10% foetal bovine serum and
L-glutamine. The sulphorhodamine B (SRB) protein stain assay
was used according to the method of Skehan et al (1990). Brieﬂy,
cells were washed with phosphate buffered saline (PBS), incubated
with 10% trichloric acetic acid in distilled water (1 h, 48C) and
washed again in distilled water. Cells were then stained for 15 to
30 min with SRB (Sigma, St. Louis, MO, USA), washed with 1%
acetic acid in distilled water and allowed to dry. Protein bound
SRB was dissolved in 10 mM Tris buffer, pH 9.4 and absorption
was measured at 540 nm. Tumour growth was calculated using
the formula: percentage tumour growth=(test well/control well)
6100%.
Isolated Limb Perfusion (ILP) model
The perfusion technique was performed as described previously (de
Wilt et al, 1999). Brieﬂy, animals were anaesthetised with Ketalin
(Apharmo, Duiven, the Netherlands) and Xylazin (Bayer B.V.,
Mijdrecht,theNetherlands).Topreventcoagulation50 IUofheparin
was injected intravenously. To keep the rat’s hind limb at a constant
temperature of 38–398C, a warm water mattress was applied.
Temperature was measured with a temperature probe on the skin
covering the tumour. The femoral artery and vein were cannulated
with silastic tubing (0.012 in inner diameter (ID), 0.025 in outer
diameter (OD); 0.025 in ID, 0.047 in OD respectively, Dow Corning,
MI, USA). Collaterals were occluded by a groin tourniquet, and isola-
tion time started when the tourniquet was tightened. An oxygenation
reservoir and a roller pump were included into the circuit. The perfu-
sion solution was 5 ml Haemaccel (Behring Pharma, Amsterdam, the
Netherlands).ThecytotoxicdrugswithorwithoutTNFwereaddedas
boluses tothe oxygenation reservoir. A roller pump (Watson Marlow,
Falmouth, UK; type 505 U) recirculated the perfusate at a ﬂow rate of
2.4 ml min
71. A washout with 5 ml oxygenated Haemaccel was
performed at the end of the perfusion.
Tumour growth was daily recorded by calliper measurement.
Tumour volume was calculated as 0.4 (A
2B), where B represents
the longest diameter and A the diameter perpendicular to B.
Assessment of limb function
Limb function was a clinical observation in which the rat’s ability
to walk and stand on the perfused limb was scored 1 day after ILP
and is an identiﬁcation for the toxicity of the used chemicals. On
this scale a severe impaired function (grade 0) means that the rat
drags its hind limb without any function; a slightly impaired func-
tion (grade 1) means the rat does not use its hind limb in a usual
matter, but stands on it when rising; an intact function of the hind
limb (grade 2) means a normal walking pattern.
Oedema was scored as no formation of oedema (7), or oedema
resulting in leg diameter increase of 1.5-fold or more (+).
Histology
The day after perfusion with actinomycin D alone or in combina-
tion with TNF tumour and muscle tissue of the perfused limb was
removed ﬁxed for 24 h in 4% formaldehyde and embedded in
parafﬁn. Muscle from the non-perfused limb was also obtained,
ﬁxed and embedded. Tissue sections of 4 mm were cut and stained
with haematoxylin and eosin, followed by examination using a
Leica DM-RXA.
Statistical analysis
Mann–Whitney U-test was used to compare tumour volumes.
Calculations were performed on a personal computer using Graph-
Pad Prism v3.0 and SPSS v8.0 for Windows 98.
RESULTS
In vitro assessment of anti-tumour activity
Previously, we demonstrated the lack of synergy between melphalan
and TNF in vitro (Manusama et al, 1996). To investigate the effect of
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was performed. Exposure of the BN-175 sarcoma cells to actinomycin
D resulted in a dose related cytotoxicity with an IC50 of 1 ng ml
71
(Figure1A).WhenusedaloneTNFhadnocytotoxicorcytostaticeffect
on this tumour cell line. Addition of TNF to actinomycin D did not
altertheIC50ofactinomycinD,indicatinglackofanysynergybetween
thetwodrugsonthiscellline.IncubationoftheTNFsensitivecellline
WEHI-164 resulted in synergy when the cells were treated with a
combination actinomycin D and TNF (Figure 1B).
In vivo tumour response to actinomycin D and TNF
after ILP
We evaluated the anti-tumour effect of actinomycin D and
melphalan with or without TNF after an isolated limb perfusion.
BN-175 soft tissue sarcoma-bearing rats were perfused with differ-
ent concentrations of actinomycin D or melphalan with or without
TNF.
Perfusions with Haemaccel (sham), or with 50 mg TNF or 5 mg
actinomycin D alone, resulted in progressive disease in all animals
(Figure 2A). Addition of 50 mg TNF to ILP with 5 mg actinomycin
D not only resulted in inhibition of the tumour growth, but also in
tumour shrinkage. At 5 days after ILP a signiﬁcant difference in the
mean tumour volume was observed as compared to sham perfu-
sions (P50.05), TNF perfusions alone (P50.05) and
actinomycin D perfusions alone (P50.05). The perfusions with a
combination of 5 mg actinomycin D and 50 mg TNF resulted in a
response rate of 40% (data not shown). When perfusions were
performed with a higher concentration of actinomycin D a further
increase in tumour response was observed. However due to the
severe toxicity with this concentration no further experiments were
performed. Perfusions with 40 mg melphalan and 50 mg TNF
resulted also in major tumour shrinkage. A signiﬁcant difference
was observed as compared to sham perfusions, TNF perfusions
alone and melphalan perfusions alone (P50.05) (Figure 2B).
Perfusions with 40 mg melphalan and 50 mg TNF resulted in a
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Figure 1 In vitro growth of BN-175 sarcoma cells (A) as a function of the
actinomycin D concentration in combination with 0 ng, 100 ng, 1000 ng
and 10000 ng TNF per ml. The mean of seven individual experiments per-
formed in duplicate are shown (+s.e.m.). And the in vitro growth of WEHI-
164 murine cells (B) as a function of the actinomycin D concentration in
combination with 0 ng, 0.01 ng, 0.05 ng, 0.1 ng, 0.5 ng and 1 ng TNF
per ml. The mean of seven individual experiments performed in duplicate
are shown (+s.e.m.).
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Figure 2 Growth curves of subcutaneous implanted BN-175 sarcoma
(A) after isolated limb perfusion with buffer alone, 50 mg TNF, 5 mg actino-
mycin D, 5 mg actinomycin D combined with 50 mg TNF and 10 mg actino-
mycin D combined with 50 mg TNF and (B) after isolated limb perfusion
with buffer alone, 50 mg TNF, 40 mg melphalan and 40 mg melphalan com-
bined with 50mg TNF. Mean (+s.e.m.) of tumour volumes are shown.
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published in various extensive series of ILP with melphalan and
TNF (Manusama et al, 1996; de Wilt et al, 1999).
Hind limb function and local toxicity
ShortlyafterILPwithactinomycin Dincombination withTNFsevere
local toxicity was observed (Table 1). Sham perfusions and perfusions
performed with TNF alone resulted in no loss of the limb function.
Some toxic side effects were observed in the rats that were perfused
with actinomycin D alone. However, after the addition of TNF to
perfusionwith actinomycin D the limbfunction dramatically deterio-
rated and strong formation of oedema was observed. After perfusion
withmelphalanwithorwithoutTNFnolossoflimbfunctionoroede-
ma formation was observed. Observation of the limb were made just
before and 1 day after perfusion with actinomycin D and TNF. Before
perfusion the rats showed a tumour in the right hind limb of approxi-
mately 1000 mm
3. Limb function at this stage was normal and no
oedema could be observed. One day after perfusion with actinomycin
D in combination with TNF the rats limb was severely swollen with
oedema and the remaining tumour was barely visible. Perfusion with
buffer or TNF alone had no effect on formation of oedema, whereas
perfusion with actinomycin D had only a marginal effect.
Tumour tissues as well as healthy tissues (muscle, skin) were
examined histopathologically. After sham perfusion some scattered
cell necrosis in tumours could be observed, correlating with
previous results (Figure 3A). In the muscle tissue from the sham
perfused limb, the skeletal muscular ﬁbre and the peripheral nuclei
could be observed in a normal pattern. The ﬁbres were intact and
no destruction of the tissue was found (Figure 3B). Rats treated
with actinomycin D alone showed massive inﬁltration of red blood
cells and haemorrhagic necrosis in the tumour 1 day after perfu-
sion (Figure 3C). Histological slides taken from the muscle of
the limb perfused with only actinomycin D showed destruction
of some of the muscle cells (Figure 3D). One day after perfusion
with TNF alone haemorrhagic necrosis in tumour was observed.
However the inﬁltration of red blood cells was not as pronounced
as after a perfusion with actinomycin D (Figure 3E). Rats treated
with TNF alone showed no damage to the muscle (Figure 3F). Rats
treated with a combination actinomycin D and TNF showed again
massive inﬁltration of red blood cells and haemorrhagic necrosis in
tumour (Figure 3G). Treatment with a combination of actinomycin
D plus TNF showed massive destruction of the muscle tissue. Cells
were torn apart and the nuclei were released in the surrounding
muscle tissue (Figure 3H).
DISCUSSION
Previously we have demonstrated that local treatment of advanced
tumours with a combination of melphalan and TNF results in high response rates. We developed a rat tumour model and showed that
results comparable to the clinic can be obtained regarding response
rate and type of response (Manusama et al, 1996; de Wilt et al,
1999; Van Der Veen et al, 2000). We used this model to evaluate
other drug combinations to improve tumour responses or to
diminish toxic side effects. We recently demonstrated that addition
of L-NAME to perfusions with melphalan with or without TNF
enhanced antitumour effects (de Wilt et al, 2000a). A mutant of
TNF, TNF-SAM2, was also investigated in this model and demon-
strated similar efﬁcacy as observed with TNF (de Wilt et al, 2000b).
In the BN-175 soft tissue sarcoma rat ILP model the usefulness of
actinomycin D was evaluated in correlation to response and toxi-
city. Actinomycin D is of particular interest both because of its
use in the ILP setting in the clinic and because of its interactions
with TNF in vitro. Treatment with melphalan in combination with
actinomycin D has been reported, but these studies showed no
signiﬁcant difference in response between treatment with the single
agent melphalan and the combination therapy (Park et al, 1980). In
previous studies with TNF and actinomycin D synergistic effects in
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Table 1 Limb function and formation of oedema in BN-175 soft tissue
sarcoma bearing rats after isolated limb perfusion with actinomycin D
and TNF
Treatment Limb function
a Oedema
b
Sham 2,2,2,2,2 7,7,7,7,7
50 mg TNF 2,2,2,2,2 7,7,7,7,7
5 mg actinomycin D 2,2,2,2,1 7,7,7,+,+
40 mg melphalan 2,2,2,2,2 7,7,7,7,7
5 mg actinomycin D and 50 mg TNF 2,2,2,1,0 +,+,+,+,+
10 mg actinomycin D and 50 mg TNF 0,0,0 +,+,+
40 mg melphalan and 50 mg TNF 2,2,2,2,2 7,7,7,7,7
aLimb functions were scored as described in Materials and Methods, and graded be-
tween 0 and 2. Grade 0: a severe impaired function, grade 1: a slightly impaired func-
tion, grade 2: an intact function.
bOedema was scored as no formation of oedema
(7), or oedema resulting in leg diameter increase of 1.5-fold or more (+).
A B
C D
E F
G H
Figure 3 Tissue sections of BN-175 tumour and muscle, haematoxylin
and eosin stained, 1 day after isolated perfusion (ILP). Histologic overview
of BN-175 tumour (A) and muscle (B) of the rat limb 1 day after sham ILP.
Histologic sections of tumour tissue (C) and muscle (D) after ILP with ac-
tinomycin D, tumour tissue (E) and muscle (F) after ILP with TNF, tumour
(G) and muscle (H) after ILP with actinomycin D plus TNF. Original mag-
niﬁcation of all sections was 166.
Actinomycin D in TNF-based ILP
ALB Seynhaeve et al
1177
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1174–1179vitro were seen (Mosende et al, 1977; Aoki et al, 1998). Especially
the TNF sensitive tumour cell line WEHI-164 responded in a
synergistic fashion to the combination of actinomycin D and
TNF. The soft tissue sarcoma BN-175 used in this study was found
to be susceptible to actinomycin D, but addition of TNF did not
result in a more cytotoxic effect on these tumour cells. These
results correlate with in vitro studies using melphalan or doxorubi-
cin in combination with TNF on several rat tumour cell lines as
colon carcinomas and osteosarcomas (van Der Veen et al, 2001).
However, in vivo combination of melphalan as well as doxorubicin
with TNF did result in strong synergy both in patients and animal
models (Lejeune et al, 1995; Eggermont et al, 1996b,c, 1997, 1999;
Manusama et al, 1996; Di Filippo et al, 1999; Van Der Veen et al,
2000). We speculated that this is due to the dual targeting of the
combination. Whereas the cytotoxic drugs preferentially target
tumour cells, TNF mainly affects the tumour associated vascula-
ture, possibly resulting in destruction of the vessels and
augmented accumulation of the drugs in the tumour tissue (Egger-
mont et al, 1997; de Wilt et al, 2000c; ten Hagen et al, 2000; Van
Der Veen et al, 2000).
In the present study an isolated limb perfusion with TNF, acti-
nomycin D or a combination in BN-175 soft tissue sarcoma
bearing rats was performed to investigate the tumour response to
these treatments. We demonstrated that the combination of actino-
mycin D with TNF was much more effective than ILP with the
single agents. However, the response rate was less pronounced
compared to previously described perfusions with melphalan or
doxorubicin in combination with TNF.
Application of ILP, with leakage below 5%, allows high local
dosages of cytotoxic agents without the systemic side-effects (Benc-
khuijsen et al, 1988; Buckley et al, 1989; Vrouenraets et al, 1999).
This means that local toxicity is the limiting factor. In our study
severe toxicity was not observed with actinomycin D or TNF when
used as single agents. However, severe toxicity occurred in the rats
that underwent an ILP with the combination therapy. This toxicity
is only local and consists of permanent loss in limb function and
massive oedema formation in the perfused limb.
In conclusion, isolated limb perfusion with actinomycin D and
TNF results in a tumour response of 40% which is not better than
the standard ILP with melphalan plus TNF. Secondly, this therapy
was accompanied by dramatic local toxicity, which increased with
higher dosages, whereas response rate improved only marginally.
Massive destruction of the muscle tissue was observed and as a
result a loss of limb function, indicating that isolated limb perfu-
sion with actinomycin D in combination with TNF should not
be explored in the clinical setting.
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